Science reporterEducation: Amherst College, BA in Physics and English; MIT, MS in Science WritingCarolyn Johnson is a science reporter. She previously covered the business of health, the pharmaceutical industry and the affordability of health care to consumers. Before coming to the Post, she covered science at the Boston Globe.Honors & Awards:
Finalist for the 2013 Pulitzer Prize in national reporting, as part of a team
The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected until the end of June. The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses.
Vaccinated people were completely protected against severe and even moderate cases of illness by the two-shot regimen in a 30,000-person trial conducted when variants had begun to complicate the pandemic in the United States and Mexico.
For people eager to put the health crisis behind them, the relief of being vaccinated is being replaced by a new worry. Is immunity a ticking clock? Should they plan a family wedding this fall? Will everyone need booster shots? When?
Now, that the Food and Drug Administration has cleared the first coronavirus vaccine for emergency use in children as young as 12, families are sure to have questions about the Pfizer-BioNTech shot and when it will become available.
The Novavax coronavirus shot, which relies on a more traditional technology, could be a key tool in the global effort to fight the pandemic.
May 10, 2021
About Carolyn Y. Johnson
Carolyn Johnson is a science reporter. She previously covered the business of health, the pharmaceutical industry and the affordability of health care to consumers. Before coming to the Post, she covered science at the Boston Globe.